Actavis CEO Says Health Law May Boost Generics Use
Feb. 15 (Bloomberg) -- Paul Bisaro, chief executive officer of Actavis Inc., talks about the impact of the U.S. Affordable Care Act on the pharmaceutical industry, so-called biosimilars, generic versions of biotechnology drugs, and the outlook for growth.
He speaks with Mark Crumpton on Bloomberg Television's "Bottom Line." (Source: Bloomberg)
How Apple Conquered China Market: Bloomberg West (01/30)
Jan. 30 -- Full episode of "Bloomberg West." Guests: GGV Capital's Hans Tung, Strategic Analytics' Neil Mawston, Evercore ISI's Ken Sena, CKE Restaurants CEO Andrew Puzder, Boost VC CEO Adam Draper and Zebra Technologies' Jill Stelfox.
Should Amazon Spin Off Its Growing Cloud Business?
TripAdvisor's Top Pick: Chicago's Langham Hotel
Dan Marino: Roger Goodell Has Done a Really Good Job
Please upgrade your Browser
Your browser is out-of-date. Please download one of these excellent browsers: